124 related articles for article (PubMed ID: 36682090)
21. Factors associated with changes in vaginal length and diameter during pelvic radiotherapy for cervical cancer.
Martins J; Vaz AF; Grion RC; Esteves SCB; Costa-Paiva L; Baccaro LF
Arch Gynecol Obstet; 2017 Dec; 296(6):1125-1133. PubMed ID: 28975498
[TBL] [Abstract][Full Text] [Related]
22. Longitudinal study of sexual function and vaginal changes after radiotherapy for cervical cancer.
Jensen PT; Groenvold M; Klee MC; Thranov I; Petersen MA; Machin D
Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):937-49. PubMed ID: 12829128
[TBL] [Abstract][Full Text] [Related]
23. Risk factors and dose-effects for bladder fistula, bleeding and cystitis after radiotherapy with imaged-guided adaptive brachytherapy for cervical cancer: An EMBRACE analysis.
Spampinato S; Fokdal LU; Pötter R; Haie-Meder C; Lindegaard JC; Schmid MP; Sturdza A; Jürgenliemk-Schulz IM; Mahantshetty U; Segedin B; Bruheim K; Hoskin P; Rai B; Huang F; Cooper R; van der Steen-Banasik E; Van Limbergen E; Sundset M; Westerveld H; Nout RA; Jensen NBK; Kirisits C; Kirchheiner K; Tanderup K;
Radiother Oncol; 2021 May; 158():312-320. PubMed ID: 33545254
[TBL] [Abstract][Full Text] [Related]
24. Assessment of an onco-sexology support and follow-up program in cervical or vaginal cancer patients undergoing brachytherapy.
Kpoghomou MA; Geneau M; Menard J; Stiti M; Almont T; Ghose B; Attal J; Delannes M; Huyghe E; Ducassou A
Support Care Cancer; 2021 Aug; 29(8):4311-4318. PubMed ID: 33411047
[TBL] [Abstract][Full Text] [Related]
25. Vaginal dilator use to promote sexual wellbeing after radiotherapy in gynecological cancer survivors.
Charatsi D; Vanakara P; Evaggelopoulou E; Simopoulou F; Korfias D; Daponte A; Kyrgias G; Tolia M
Medicine (Baltimore); 2022 Jan; 101(4):e28705. PubMed ID: 35089231
[TBL] [Abstract][Full Text] [Related]
26. Initiatives for education, training, and dissemination of morbidity assessment and reporting in a multiinstitutional international context: Insights from the EMBRACE studies on cervical cancer.
Kirchheiner K; Smet S; Spampinato S; Jensen NBK; Vittrup AS; Fokdal L; Najjari-Jamal D; Westerveld HG; Lindegaard JC; Kirisits C; De Leeuw A; Schmid MP; Tan LT; Nout RA; Jürgenliemk-Schulz IM; Pötter R; Tanderup K;
Brachytherapy; 2020; 19(6):837-849. PubMed ID: 32978080
[TBL] [Abstract][Full Text] [Related]
27. Impact of chemoradiotherapy on vaginal and sexual function of patients with FIGO IIb cervical cancer.
Ljuca D; Marošević G
Bosn J Basic Med Sci; 2011 Feb; 11(1):62-4. PubMed ID: 21342145
[TBL] [Abstract][Full Text] [Related]
28. Vaginal dose-surface maps in cervical cancer brachytherapy: Methodology and preliminary results on correlation with morbidity.
Serban M; de Leeuw AAC; Tanderup K; Jürgenliemk-Schulz IM
Brachytherapy; 2021; 20(3):565-575. PubMed ID: 33741274
[TBL] [Abstract][Full Text] [Related]
29. Sexual function after intracavitary vaginal brachytherapy for early-stage endometrial carcinoma.
Quick AM; Seamon LG; Abdel-Rasoul M; Salani R; Martin D
Int J Gynecol Cancer; 2012 May; 22(4):703-8. PubMed ID: 22398710
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of outcomes in patients of cervical Cancer with lower one third vaginal involvement: A single institutional experience.
Gurram L; Patil R; Chopra S; Maheshwari A; Shylasree TS; Gupta S; Ghosh J; Gulia S; Ghadi Y; A D; Mahantshetty U
Gynecol Oncol; 2020 Nov; 159(2):359-364. PubMed ID: 32829963
[TBL] [Abstract][Full Text] [Related]
31. Vaginal dose de-escalation in image guided adaptive brachytherapy for locally advanced cervical cancer.
Mohamed S; Lindegaard JC; de Leeuw AA; Jürgenliemk-Schulz I; Kirchheiner K; Kirisits C; Pötter R; Tanderup K
Radiother Oncol; 2016 Sep; 120(3):480-485. PubMed ID: 27267048
[TBL] [Abstract][Full Text] [Related]
32. Clinical outcomes of definitive chemoradiation followed by intracavitary pulsed-dose rate image-guided adaptive brachytherapy in locally advanced cervical cancer.
Castelnau-Marchand P; Chargari C; Maroun P; Dumas I; Del Campo ER; Cao K; Petit C; Martinetti F; Tafo-Guemnie A; Lefkopoulos D; Morice P; Haie-Meder C; Mazeron R
Gynecol Oncol; 2015 Nov; 139(2):288-94. PubMed ID: 26364808
[TBL] [Abstract][Full Text] [Related]
33. Co-occurrence of symptoms after radiochemotherapy in locally advanced cervix cancer patients: a cluster analysis.
Pelizzola M; Tanderup K; Chopra S; Jürgenliemk-Schulz IM; Nout R; Kirchheiner K; Spampinato S
Acta Oncol; 2023 Nov; 62(11):1479-1487. PubMed ID: 37906286
[TBL] [Abstract][Full Text] [Related]
34. Assessment of Parametrial Response by Growth Pattern in Patients With International Federation of Gynecology and Obstetrics Stage IIB and IIIB Cervical Cancer: Analysis of Patients From a Prospective, Multicenter Trial (EMBRACE).
Yoshida K; Jastaniyah N; Sturdza A; Lindegaard J; Segedin B; Mahantshetty U; Rai B; Jürgenliemk-Schulz I; Haie-Meder C; Sasaki R; Pötter R
Int J Radiat Oncol Biol Phys; 2015 Nov; 93(4):788-96. PubMed ID: 26530747
[TBL] [Abstract][Full Text] [Related]
35. A volumetric analysis of GTV
Jastaniyah N; Yoshida K; Tanderup K; Lindegaard JC; Sturdza A; Kirisits C; Šegedin B; Mahantshetty U; Rai B; Jürgenliemk-Schulz IM; Haie-Meder C; Banerjee S; Pötter R;
Radiother Oncol; 2016 Sep; 120(3):404-411. PubMed ID: 27452409
[TBL] [Abstract][Full Text] [Related]
36. Clinical outcome of protocol based image (MRI) guided adaptive brachytherapy combined with 3D conformal radiotherapy with or without chemotherapy in patients with locally advanced cervical cancer.
Pötter R; Georg P; Dimopoulos JC; Grimm M; Berger D; Nesvacil N; Georg D; Schmid MP; Reinthaller A; Sturdza A; Kirisits C
Radiother Oncol; 2011 Jul; 100(1):116-23. PubMed ID: 21821305
[TBL] [Abstract][Full Text] [Related]
37. The acceptability, feasibility, and efficacy (phase I/II study) of the OVERcome (Olive Oil, Vaginal Exercise, and MoisturizeR) intervention to improve dyspareunia and alleviate sexual problems in women with breast cancer.
Juraskova I; Jarvis S; Mok K; Peate M; Meiser B; Cheah BC; Mireskandari S; Friedlander M
J Sex Med; 2013 Oct; 10(10):2549-58. PubMed ID: 23635341
[TBL] [Abstract][Full Text] [Related]
38. Quality of life and sexual function after type C2/type III radical hysterectomy for locally advanced cervical cancer: a prospective study.
Plotti F; Sansone M; Di Donato V; Antonelli E; Altavilla T; Angioli R; Panici PB
J Sex Med; 2011 Mar; 8(3):894-904. PubMed ID: 21143414
[TBL] [Abstract][Full Text] [Related]
39. A nurse-led sexual rehabilitation intervention after radiotherapy for gynecological cancer.
Bakker RM; Mens JW; de Groot HE; Tuijnman-Raasveld CC; Braat C; Hompus WC; Poelman JG; Laman MS; Velema LA; de Kroon CD; van Doorn HC; Creutzberg CL; Ter Kuile MM
Support Care Cancer; 2017 Mar; 25(3):729-737. PubMed ID: 27787681
[TBL] [Abstract][Full Text] [Related]
40. Dose-volume effect relationships for late rectal morbidity in patients treated with chemoradiation and MRI-guided adaptive brachytherapy for locally advanced cervical cancer: Results from the prospective multicenter EMBRACE study.
Mazeron R; Fokdal LU; Kirchheiner K; Georg P; Jastaniyah N; Šegedin B; Mahantshetty U; Hoskin P; Jürgenliemk-Schulz I; Kirisits C; Lindegaard JC; Dörr W; Haie-Meder C; Tanderup K; Pötter R;
Radiother Oncol; 2016 Sep; 120(3):412-419. PubMed ID: 27396811
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
